Innoviva Inc Revenue Growth Rates (INVA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Innoviva Inc   (NASDAQ: INVA)
 

INVA's Revenue Growth by Quarter and Year

Innoviva Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

INVA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 119.59
1st Quarter March 90.83
FY 210.42

INVAs Annual Revenue
Innoviva Inc 's Revenue in the fiscal year 2025 $ 384.67 millions
Innoviva Inc 's Revenue in the fiscal year 2024 $ 417.87 millions
Innoviva Inc 's Revenue in the fiscal year 2023 $ 310.46 millions
Innoviva Inc 's Revenue in the fiscal year 2022 $ 322.88 millions
Innoviva Inc 's Revenue in the fiscal year 2021 $ 391.87 millions




INVA Revenue second quarter 2026 Y/Y Growth Comment
Innoviva Inc reported Revenue improvement of 28.39% year on year in the second quarter 2026, to $ 119.59 millions, this is lower than Innoviva Inc 's recent average Revenue rise of 76.78%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 135 other companies have achieved higher Revenue growth. While Innoviva Inc ' s Revenue rise of 28.39% ranks overall at the positon no. 3155 in the second quarter 2026.


INVA Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 21.67 % 5.01 % 49.7 %
3rd Quarter September - -5.54 % 52.27 % 3.93 %
2nd Quarter June 28.39 % -28.59 % 61.07 % -25.16 %
1st Quarter March 11.69 % -10.47 % 15.65 % -12.79 %
FY   - -7.94 % 32.54 % -

Financial Statements
Innoviva Inc 's second quarter 2026 Revenue $ 119.59 millions INVA's Income Statement
Innoviva Inc 's second quarter 2025 Revenue $ 93.15 millions Quarterly INVA's Income Statement


INVA Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 9.08 % -15.31 % 22.8 %
3rd Quarter September - 7.93 % -18.41 % -13.69 %
2nd Quarter June 31.66 % 14.55 % 43.62 % 3.12 %
1st Quarter March -17.18 % -9.78 % 5.81 % 36.97 %
FY (Year on Year)   - -7.94 % 32.54 % -


Back to INVA Growth rate Comparisons >> Back to INVA Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #136
Healthcare Sector #425
Overall #3155

Revenue Y/Y Growth Statistics
High Average Low
975.13 % 76.78 % -96.64 %
(Sep 30 2015)   (Dec 31 2013)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #136
Healthcare Sector #425
Overall #3155
Revenue Y/Y Growth Statistics
High Average Low
975.13 % 76.78 % -96.64 %
(Sep 30 2015)   (Dec 31 2013)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Innoviva Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
2270.81 % 65.04 % -98.87 %
(Mar 31 2012)  


INVA's II. Quarter Q/Q Revenue Comment
Innoviva Inc achieved in the II. Quarter 2026 below company average Revenue jump of 31.66% quarter on quarter, to $ 119.59 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 14.55% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 38 other companies have achieved higher Revenue quarter on quarter growth. While Innoviva Inc 's Revenue growth quarter on quarter, overall rank is 352.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #39
Healthcare Sector #80
Overall #352
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #39
Healthcare Sector #80
Overall #352
Revenue Q/Q Growth Statistics
High Average Low
2270.81 % 65.04 % -98.87 %
(Mar 31 2012)  


INVA's II. Quarter Q/Q Revenue Comment
Innoviva Inc achieved in the II. Quarter 2026 below company average Revenue jump of 31.66% quarter on quarter, to $ 119.59 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 14.55% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 38 other companies have achieved higher Revenue quarter on quarter growth. While Innoviva Inc 's Revenue growth quarter on quarter, overall rank is 352.


Innoviva Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 420.63 $ 394.19 $ 384.67 $ 365.14 $ 371.05
Y / Y Revenue Growth (TTM) 13.36 % -3.47 % -7.95 % -11.71 % -1.59 %
Year on Year Revenue Growth Overall Ranking # 2759 # 339 # 128 # 239 # 560
Seqeuential Revenue Change (TTM) 6.71 % 2.47 % 5.35 % -1.59 % -9.14 %
Seq. Revenue Growth (TTM) Overall Ranking # 3155 # 2329 # 1261 # 892 # 442


Cumulative Revenue growth Comment
Although Innoviva Inc 's Annual Revenue growth year on year were below company's average 76.78% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 13.36% year on year, from -3.47% in Mar 31 2026.

In the Healthcare sector 390 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 339 to 2759.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 136
Healthcare Sector # 391
Overall # 2759

Revenue TTM Y/Y Growth Statistics
High Average Low
975.13 %
 76.78 %
-96.64 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 136
Sector # 425
S&P 500 # 3155
Cumulative Revenue growth Comment
Although Innoviva Inc 's Annual Revenue growth year on year were below company's average 76.78% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 13.36% year on year, from -3.47% in Mar 31 2026.

In the Healthcare sector 390 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 339 to 2759.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 136
Healthcare Sector # 391
Overall # 2759

Revenue TTM Y/Y Growth Statistics
High Average Low
975.13 %
76.78 %
-96.64 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 136
Sector # 425
S&P 500 # 3155




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
INVA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Coya Therapeutics Inc 48.97%$ 48.974 millions
Travere Therapeutics Inc 48.17%$ 48.174 millions
Halozyme Therapeutics Inc 47.67%$ 47.673 millions
Eli Lilly And Company47.67%$ 47.670 millions
Rhythm Pharmaceuticals Inc 46.91%$ 46.911 millions
Axsome Therapeutics Inc 45.54%$ 45.543 millions
Guardant Health Inc 44.33%$ 44.332 millions
Omada Health Inc 43.27%$ 43.273 millions
Mannkind Corporation42.92%$ 42.922 millions
Butterfly Network Inc 42.47%$ 42.466 millions
Beta Bionics Inc 42.26%$ 42.261 millions
Vyne Therapeutics Inc 40.58%$ 40.580 millions
Qhslab Inc 39.98%$ 39.978 millions
Coherus Oncology inc 39.53%$ 39.526 millions
Neurocrine Biosciences Inc 39.49%$ 39.491 millions
Ss Innovations International Inc39.39%$ 39.393 millions
Assembly Biosciences Inc 38.94%$ 38.936 millions
Edap Tms Sa38.85%$ 38.847 millions
Picard Medical Inc 38.62%$ 38.620 millions
Hims and Hers Health Inc 38.41%$ 38.409 millions
Aquestive Therapeutics Inc 38.15%$ 38.149 millions
Mirum Pharmaceuticals Inc 37.92%$ 37.922 millions
Natera Inc 37.71%$ 37.715 millions
Zomedica Corp 36.59%$ 36.588 millions
Kura Oncology Inc 36.54%$ 36.538 millions
Scientific Industries Inc 36.02%$ 36.022 millions
Ceribell Inc 35.85%$ 35.852 millions
Intelligent Bio Solutions Inc 35.78%$ 35.777 millions
The Pennant Group Inc 35.76%$ 35.755 millions
Quanterix Corporation35.42%$ 35.416 millions


About Innoviva Inc Revenue Growth Rates (INVA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Innoviva Inc (CIK 1080014).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-335235
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Innoviva Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.